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Abstract
Background: Oxidative stress and inflammation are two critical factors that drive the formation of plaques in
atherosclerosis. Nrf2 is a redox-sensitive transcription factor that upregulates a battery of antioxidative genes and
cytoprotective enzymes that constitute the cellular response to oxidative stress. Our previous studies have shown that
disruption of Nrf2 in mice (Nrf2
2/2) causes increased susceptibility to pulmonary emphysema, asthma and sepsis due to
increased oxidative stress and inflammation. Here we have tested the hypothesis that disruption of Nrf2 in mice causes
increased atherosclerosis.
Principal Findings: To investigate the role of Nrf2 in the development of atherosclerosis, we crossed Nrf2
2/2 mice with
apoliporotein E-deficient (ApoE
2/2) mice. ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice were fed an atherogenic diet for 20 weeks,
and plaque area was assessed in the aortas. Surprisingly, ApoE
2/2 Nrf2
2/2 mice exhibited significantly smaller plaque area
than ApoE
2/2 controls (11.5% vs 29.5%). This decrease in plaque area observed in ApoE
2/2 Nrf2
2/2 mice was associated
with a significant decrease in uptake of modified low density lipoproteins (AcLDL) by isolated macrophages from ApoE
2/2
Nrf2
2/2 mice. Furthermore, atherosclerotic plaques and isolated macrophages from ApoE
2/2 Nrf2
2/2 mice exhibited
decreased expression of the scavenger receptor CD36.
Conclusions: Nrf2 is pro-atherogenic in mice, despite its antioxidative function. The net pro-atherogenic effect of Nrf2 may
be mediated via positive regulation of CD36. Our data demonstrates that the potential effects of Nrf2-targeted therapies on
cardiovascular disease need to be investigated.
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Introduction
Cardiovascular disease is responsible for 40% of all deaths in the
US and remains a global public health problem [1]. Atheroscle-
rosis, which is characterized by deposition of fatty plaques in the
arterial walls, is a leading cause of cardiovascular disease.
Atherosclerotic plaques form as a result of macrophage accumu-
lation in the sub-endothelial space of large arteries [2,3]. Once in
the arterial wall, macrophages absorb LDL cholesterol molecules,
causing them to develop into foam cells. These cells in turn release
chemokines and cytokines, which further enhance inflammatory
cell recruitment and perpetuate plaque formation.
Numerous reports indicate that oxidative stress and chronic
inflammation are key contributors to the pathogenesis of
atherosclerosis. Oxidative stress has several effects on vascular
cells, including direct damage of cell membranes [4], and impaired
nitric oxide-dependent endothelial-dependent vasomotion [5].
Oxidative stress also causes the oxidation of LDL cholesterol,
which enhances LDL uptake by macrophages. Native LDL is not
readily absorbed by macrophages. However, oxidized LDL
(oxLDL) is rapidly endocytosed by macrophages via scavenger
receptors, such as CD36 and scavenger receptor A (SR-A), which
localize to the surface of macrophages [2]. oxLDL also has
multiple pro-inflammatory properties, including promotion of
monocyte adhesion to the endothelial cell wall and increased
expression of pro-inflammatory chemokines [6].
Despite ample evidence that oxidative stress plays a key role in
atherogenesis, attempts to inhibit oxidative stress have been met
with mixed success. In animal models, probucol, vitamin E,
butylated hydroxytoluene, and N,N9-diphenylphenylenediamine
have been shown to reduce the rate of progression of
atherosclerosis [7–10]. However, clinical trials of antioxidants in
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[11,12]. One explanation for this failure is that existing
antioxidants are directed against free radicals or single-electron
oxidants (superoxide, peroxynitrate), whereas non-radical oxi-
dants, e.g. hydrogen peroxide, remain largely intact [13]. Indeed,
deletions of p47
phox and gp91
phox subunits of NADPH oxidase
inhibited superoxide generation in the aorta of ApoE
2/2 mice, but
the effects on atherosclerosis were equivocal [14–16]; over-
expression of Cu/Zn superoxide dismutase (SOD), which converts
superoxide to hydrogen peroxide, did not attenuate atherosclerosis
in ApoE
2/2 mice [17]. In contrast, over-expression of catalase, an
enzyme decomposing hydrogen peroxide, or both catalase and
SOD markedly inhibited the progression of atherosclerotic lesions
[17]. This demonstrates that novel therapies targeting oxidative
stress should be further pursued.
Nuclear factor E2-related factor 2 (Nrf2) is a member of the
basic leucine zipper (bZIP) family of transcription factors that
share a conserved cap ‘n’ collar domain. Nrf2 functions as a
critical mediator of an adaptive response to counteract oxidative
stress. In the presence of oxidative stress, Nrf2 translocates to the
nucleus, where it binds to the antioxidant response element (ARE),
and activates the coordinate expression of a cohort of antioxidative
and electrophile detoxification genes [18]. Activation of Nrf2
causes upregulation of multiple antioxidative enzymes, including
several proteins that function to increase the levels of reduced
glutathione, which is a major intracellular antioxidant. Our
previous studies have shown that mice that are deficient in Nrf2 are
characterized by high levels of oxidative stress and an inappro-
priate inflammatory response following exposure to a variety of
stressors including chronic cigarette smoke-mediated emphysema
[19], allergic asthma [20], and endotoxin and acute peritonitis
induced septic shock [21].
Several studies suggest that Nrf2 may alter susceptibility to
atherosclerosis. Treatment of mouse macrophages with oxLDL
causes activation of Nrf2 and increased glutathione synthesis [22],
indicating that Nrf2 is an important component of the macro-
phage response to oxLDL. Also, elevated glutathione levels are
protective against atherosclerotic plaques in mice [23], and
decreased serum glutathione levels correlate with increased risk
of coronary heart disease in humans [24]. Furthermore, the Nrf2-
dependent gene heme oxygenase 1 (Ho-1) has been shown to
reduce the chemotaxis of monocytes following exposure to oxLDL
[25], indicating that Ho-1 may inhibit monocyte recruitment to
the arterial walls. Accordingly, Ho-1 deficiency is associated with
accelerated progression of atherosclerosis in mice [26].
In vitro studies that examined the effects of endothelial shear
stress showed that anti-atherogenic laminar flow induces Nrf2-
dependent gene expression, while pro-atherogenic oscillatory flow
inhibits Nrf2 activity [27,28], demonstrating that Nrf2 activity
may be important for maintaining the structural integrity of
endothelial cells. Also Nrf2 decreases expression of vascular cell
adhesion molecule 1 (VCAM-1) in endothelial cells, suggesting that
Nrf2 inhibits monocyte adhesion [28]. On the other hand, Nrf2
increases expression of the pro-atherogenic scavenger receptor
CD36 [29,30]. Despite the indirect evidence that this critical
transcription factor may be important in the pathogenesis of
atherosclerosis, the role of Nrf2 in atherosclerosis has yet to be
investigated in vivo.
To address whether Nrf2 is a modifier of atherosclerosis we
utilized ApoE
2/2 mice, an established model of hyperlipidemia
and atherosclerosis. We compared plaque formation and progres-
sion in ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice. Despite the
antioxidative function of Nrf2, we observed that ApoE
2/2
Nrf2
2/2 mice developed fewer plaques than ApoE
2/2 controls.
We also observed that isolated macrophages from ApoE
2/2 Nrf2
2/2
mice showed decreased uptake of modified LDL, which was
associated with decreased expression of the scavenger receptor
CD36. Thus, Nrf2 is pro-atherogenic in mice.
Results
Nrf2 Deficient Mice Exhibit Reduced Atherosclerotic
Plaques
ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice were fed high fat diet for
10 or 20 weeks, and plaque formation was quantified along the
entire aorta in the en face preparation. Plaques were located
throughout the entire aorta, although the heaviest plaque burden
was observed in the aortic arch (Fig. 1). Unexpectedly, ApoE
2/2
Nrf2
2/2 mice exhibited a 67% decrease in plaque area after 10
weeks and a 61% decrease after 20 weeks, compared to ApoE
2/2
mice (p,0.05, Fig. 1A & B). For both genotypes, there was no
significant difference between sexes (Fig. 1B).
At the aortic origin, measurements of cross-sectional plaque
area were consistent with the en face preparation. Compared to
ApoE
2/2 mice, Nrf2-deficient animals exhibited a 36% decrease in
plaque size after 10 weeks and a 27% decrease after 20 weeks,
which were both statistically significant (Fig 2A & B). As with the en
face preparation, there was no significant difference between sexes
(data not shown). We did not observe significant differences in
plaque composition between ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice
in terms of necrotic, fibrotic, or macrophage-rich regions (data not
shown).
Nrf2 Deficient Mice Have Improved Aortic Stiffness
Atherosclerotic plaques cause arteries to become stiffer. We
measured aortic diameter at the root, to determine whether the
difference in aortic plaques observed in ApoE
2/2 and ApoE
2/2
Nrf2
2/2 mice correlated with altered aortic diameters. Aortic
diameter was measured at the aortic sinus during both systole and
diastole using two-dimensional echocardiography in mice that
were fed a high fat diet for 20 weeks. We observed that ApoE
2/2
Nrf2
2/2 mice exhibited significantly decreased aortic end-diastolic
diameter, compared to ApoE
2/2 mice (Table 1 and Fig 3). Also,
the percent difference between end-diastolic and end-systolic
diameter was significantly increased in ApoE
2/2 Nrf2
2/2 mice,
suggesting that the aortas from ApoE
2/2 Nrf2
2/2 mice were less
stiff. This decreased aortic stiffness in ApoE
2/2 Nrf2
2/2 mice
correlated with the decreased plaque area observed in these mice,
demonstrating that atherosclerotic plaques impair normal aortic
physiology. As expected, there was no difference between sexes
(data not shown).
Serum Glucose and Cholesterol in ApoE
2/2 and ApoE
2/2
Nrf2
2/2 Mice
To take into account potential differences in the lipid profiles of
the two groups, we measured total cholesterol, LDL cholesterol,
and triglycerides in fasted ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice
after 20 weeks on a high fat diet. We did not observe any
significant change in concentration of serum LDL or total
cholesterol between ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice
(Table 2). However, ApoE
2/2 Nrf2
2/2 mice exhibited a significant
increase in serum triglycerides. Furthermore, we observed that
ApoE
2/2 Nrf2
2/2 mice exhibited significantly elevated serum
glucose concentrations, compared to ApoE
2/2 mice (Table 2).
Since elevated triglycerides and glucose are both associated with
promotion of atherosclerosis [1], these measurements do not
explain why ApoE
2/2 Nrf2
2/2 mice exhibited decreased athero-
sclerotic plaque formation.
Nrf2 Promotes Atherosclerosis
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Macrophages take up oxLDL more readily than native LDL.
Therefore, we measured oxLDL levels in the serum. We did not
detect any significant differences in oxLDL levels between ApoE
2/2
and ApoE
2/2 Nrf2
2/2 mice (Fig. 4A). Thus, the decrease in
atherosclerotic plaque formation in ApoE
2/2 Nrf2
2/2 mice is not
due to decreased oxLDL in the serum. We also examined oxidative
stress in the liver. The concentration of malondialdehyde (MDA),
which is a marker of lipid peroxidation, was elevated significantly in
the liver of ApoE
2/2 Nrf2
2/2 mice (Fig. 4B). The increased MDAin
the liver is consistent with the antioxidative function of Nrf2, butit is
contradictory to the decrease in plaque area observed in ApoE
2/2
Figure 1. En face plaque area of aortas from ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice. (A) Representative images of aortas from ApoE
2/2 and
ApoE
2/2 Nrf2
2/2 mice after 20 weeks on a high fat diet, showing plaques stained with oil red O. (B) Quantification of percent plaque area 6SEM after
10 and 20 weeks on a high fat diet. *p,0.05 by a two-tailed Student’s t-test. N=4–6 per group.
doi:10.1371/journal.pone.0003791.g001
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2/2 mice. This suggests that even though Nrf2 reduces
oxidative stress, it still promotes atherosclerotic plaque development
via a different mechanism.
ApoE
2/2 Nrf2
2/2 Macrophages Exhibited Decreased
Modified LDL Uptake
Macrophages readily absorb modified LDL, via scavenger
receptors. Therefore, to determine whether macrophages from
ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice differ in their ability to
absorb modified LDL, bone marrow-derived macrophages from
ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice were isolated and incubated
with fluorescently-labeled acetylated LDL (AcLDL). AcLDL is a
commonly used surrogate for oxLDL. Macrophages from ApoE
2/2
Nrf2
2/2 mice exhibited decreased uptake of AcLDL, as assessed by
flow cytometry (Fig. 5). Therefore, the decrease in aortic plaques in
ApoE
2/2 Nrf2
2/2 mice was associated with decreased uptake of
AcLDL by macrophages.
ApoE
2/2 Nrf2
2/2 Mice Exhibited Decreased CD36
Expression
CD36 is a scavenger receptor that is responsible for recognition of
modified LDL,and it playsan important rolein plaque development.
To determine whether Nrf2 regulates CD36 expression, bone
marrow-derived macrophages were isolated from ApoE
2/2 and
ApoE
2/2 Nrf2
2/2 mice. CD36 expression was determined by
quantitative PCR. There was no significant difference in CD36
expression between ApoE
2/2 and ApoE
2/2Nrf2
2/2 mice under non-
stressed conditions (Fig. 6A). However, treatment of macrophages
with oxLDL for 24 h at 37uC caused a significant increase in CD36
expression in ApoE
2/2, but not ApoE
2/2 Nrf2
2/2 mice. Further-
more, Ho-1, glutamate-cysteine ligase (Gclm), and NAD(P)H:quinone
oxidoreductase-1 (Nqo1), which are known antioxidative targets of
Nrf2, were induced by oxLDL in an Nrf2-dependent manner
( F i g .6 B – D ) .T h e r e f o r e ,d e s p i t et h ef u n c t i o no fN r f 2a sam a s t e r
regulator of antioxidative genes, Nrf2 induces the pro-atherogenic
gene CD36 following exposure to oxLDL. We also determined that
gene expression of scavenger receptor A (Sra), Srb-1,a n dl o wd e n s i t y
lipoprotein receptor (Ldlr) were not elevated in macrophages from
either ApoE
2/2 or ApoE
2/2 Nrf2
2/2 mice in response to oxLDL
(data not shown). Furthermore, we did not detect any increases in the
pro-inflammatory cytokine Tnfa and chemokine Ccl-2 in response to
oxLDL (data not shown).
We also examined in vivo levels of CD36 protein within plaques
from ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice that were fed a high fat
diet for 20 weeks. CD36 staining was significantly reduced in
plaques from ApoE
2/2 Nrf2
2/2 mice, compared to ApoE
2/2 mice
(Fig. 6E–F). Thus, Nrf2 increases pro-atherogenic CD36 protein
levels in aortic plaques.
Discussion
Our findings demonstrate that Nrf2
2/2 mice have a decreased
susceptibility to ApoE-mediated atherosclerotic plaque formation.
This result was surprising in light of the well-established role of
Nrf2 as a critical determinant of the response to counteract
oxidative stress. Consistent with this antioxidative role of Nrf2, we
demonstrated that ApoE
2/2 Nrf2
2/2 mice exhibit significantly
elevated lipid peroxidation in the liver, and macrophages from
ApoE
2/2 Nrf2
2/2 mice failed to induce expression of key Nrf2-
regulated antioxidative genes Ho-1, Gclm, and Nqo1 in response to
oxLDL. Wu et al. previously demonstrated that oxidative stress is
associated with elevated blood pressure [31]. One limitation of our
study is that we did not measure blood pressure in ApoE
2/2 and
ApoE
2/2 Nrf2
2/2 mice. However, our data in mice on the
C57BL/6 background following 20 weeks on a high fat diet
showed that there is no difference in mean blood pressure between
wild-type and Nrf2
2/2 mice (82.262.7 and 86.463.4 mm Hg,
respectively). Hartley et al. demonstrated that blood pressure in
ApoE
2/2 mice is not significantly elevated, compared to wild-type
mice [32]. Thus, we do not predict any Nrf2-dependent effects on
blood pressure.
Figure 2. Cross-sectional plaque area at the aortic root. (A)
Representative images of aortic cross-sections of ApoE
2/2 and ApoE
2/2
Nrf2
2/2 male mice after 20 weeks on a high fat diet, showing plaques in
the arterial walls (asterisks). (B) Quanitfication of plaque area 6SEM
after 10 and 20 weeks on a high fat diet. *p,0.05 by a two-tailed
Student’s t-test. N=4–6 per group.
doi:10.1371/journal.pone.0003791.g002
Table 1. End-diastolic and end-systolic diameter of ascending aorta after 20 weeks on a high fat diet.
End-Diastolic Diam. (mm) End-Systolic Diam. (mm) Ratio (ESD-EDD/EDD)
ApoE
2/2 1.2260.04* 1.3660.05 0.1160.02*
ApoE
2/2 Nrf2
2/2 1.0760.03 1.2760.02 0.1960.02
*p,0.05 by a two-tailed Student’s t-test.
Values are mean6SEM. Sample size for ApoE
2/2 and ApoE
2/2 Nrf2
2/2 is 9 and 13, respectively.
doi:10.1371/journal.pone.0003791.t001
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antioxidative genes and cytoprotective enzymes, including several
enzymes responsible for the synthesis of glutathione [18]. Nrf2 also
induces expression of Ho-1, which is a key antioxidant enzyme.
Both glutathione and Ho-1 have been shown to prevent
atherosclerosis in mice [23,26]. However, we demonstrated in
this study that the master regulator of these antioxidative proteins
promotes the development of atherosclerosis. Therefore, it appears
as if Nrf2 has conflicting functions in the development of
atherosclerosis. In this study, we confirmed the findings of Ishii
et al. [29] that macrophages lacking Nrf2 take up significantly less
modified LDL. Therefore, the antioxidative function of Nrf2 is
superseded by its promotion of modified LDL uptake in
macrophages.
Macrophages utilize scavenger receptors, such as CD36 and
scavenger receptor A (SR-A), to recognize and endocytose
modified LDL. ApoE
2/2 CD36
2/2 mice internalize less modified
LDL and have a substantial decrease in atherosclerotic lesion size,
compared to ApoE
2/2 controls [33]. Our data shows that oxLDL
induced CD36 expression in macrophages from ApoE
2/2, but not
ApoE
2/2 Nrf2
2/2 mice. In addition, oxLDL did not induce Sra,
Srb-1,o rLdlr expression in ApoE
2/2 mice, consistent with previous
studies that demonstrate the specific role of Nrf2 in the expression
of CD36, but not of other scavenger receptors [29,30]. Further-
more, CD36 has been shown to contain an ARE in its promoter,
which is recognized by Nrf2 [30]. We also showed that ApoE
2/2
Nrf2
2/2 mice exhibited reduced levels of CD36 protein in the
atherosclerotic plaques. Taken together, our data suggest that
Nrf2-mediated CD36 expression is a major pathway by which
modified LDL becomes incorporated into atheroma. In the
absence of Nrf2, even in the face of greater oxidative stress,
atherosclerosis is markedly reduced.
We did not observe any significant alteration in the serum levels
of total cholesterol or LDL after 20 weeks on a high fat diet, which
demonstrates that Nrf2 does not have a net effect on circulating
cholesterol. However, we did observe that ApoE
2/2 Nrf2
2/2 mice
have significantly elevated triglyceride levels. This is consistent
with previous studies demonstrating that CD36-deficient mice have
elevated plasma triglyceride levels [34,35], further supporting the
role of CD36 in ApoE
2/2 Nrf2
2/2 mice. Mechanisms of the
concomitant increase in blood glucose in Nrf2 deficient mice are
less clear, although it may be attributed to dyslipidemia-induced
insulin resistance. Our data suggests that CD36 deficiency in Nrf2-
deficient mice is a powerful antiatherogenic factor, which can
override multiple pro-atherogenic conditions, which were present
in the ApoE
2/2 Nrf2
2/2 mice, including oxidative stress,
hypertriglyceridemia and hyperglycemia. Nevertheless, Nrf2 is a
transcription factor that regulates numerous genes, and it is
possible that Nrf2 deficiency alters development of atherosclerosis
via more than one mechanism.
In conclusion, our data clearly demonstrate that Nrf2
2/2 mice
are less susceptible to ApoE-mediated plaque formation, and this is
associated with decreased CD36 expression and decreased LDL
Figure 3. Representative 2 D mode echocardiogram images from ApoE
2/2 and ApoE
2/2 Nrf2
2/2mice following exposure to high fat
diet for 20 weeks. Aortic diameters (lines) and plaques (arrowheads) are shown. Aortic root (Ao), ascending aorta (AsAo), right atrium (RA), left
ventricle outflow tract (LVOT).
doi:10.1371/journal.pone.0003791.g003
Table 2. Serum lipid and glucose levels (total cholesterol, low
density lipoprotein, and triglycerides).
TC (mg/dl) LDL (mg/dl) TG (mg/dl)
Glucose
(mg/dl)
ApoE
2/2 739627 590620 79610* 15065*
ApoE
2/2 Nrf2
2/2 706685 618640 117611 201613
*p,0.05 by a two-tailed Student’s t-test.
Values represent mean6SEM. N=12 per group.
doi:10.1371/journal.pone.0003791.t002
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proposed as a potential therapeutic approach for a variety of
diseases. Considering the profound effect of Nrf2-dependent
transcriptional induction of CD36 in macrophages and the
resulting impact on atherosclerosis, it is important to consider
the potential pro-atherosclerotic effects of Nrf2 when designing
Nrf2-targeted therapies.
Materials and Methods
Animals and Treatments
ApoE
2/2 mice maintained on a C57BL/6J background were
obtained from Jackson Laboratories (Bar Harbor, ME), and were
crossed with C57BL/6J Nrf2
2/2 mice to generate ApoE
2/2 Nrf2
+/+
and ApoE
2/2 Nrf2
2/2 mice. Mice were housed under controlled
conditions for temperature and humidity, using a 12 h light/dark
cycle. Eight week old mice were fed an atherogenic diet
(TD.94059) from Harlan Teklad (Madison, WI) for 10 or 20
weeks. For all experiments, mice were age- and sex-matched.
When appropriate, data for both sexes was combined. Mice
were fasted for 6 h prior to analyses. All experimental protocols
were performed in accordance with the standards established by
the US Animal Welfare Acts, as set forth in NIH guidelines and
in the Policy and Procedures Manual of the Johns Hopkins
University Animal Care and Use Committee.
Measurement of Plaques
For en face analysis, aortas were analyzed as described [36].
Briefly, aortas were removed, fixed in 10% formalin, cut
longitudinally, stained with oil red O, and photographed. Percent
plaque area was measured using Image Pro Express software
(MediaCybernetics, Silver Spring, MD). For cross-section analysis
of plaque formation, aortas were fixed in 10% formalin and
embedded in paraffin. Sections from the aortic root were stained
with hematoxylin and eosin, and images were captured with an
Olympus BX41 microscope. Area calculations were performed
using Image-J software (NIH, Bethesda, MD, USA). Fibrotic areas
were estimated based on percent area of intimal plaque positive for
Masson’s trichrome stain (Richard-Allan Scientific, Kalamazoo,
MI). Macrophage-rich areas were identified with Mac3 (BD
Pharmingen) immunostaining. 4–8 sections from each animal
were used for calculations.
Aortic Stiffness
Aortic diameter was measured in the ascending aorta of
conscious mice via two-dimensional echocardiography, using a
Sequoia Acuson C256 (Siemens Medical Solutions USA, Inc.,
Malvern, PA) ultrasound machine, equipped with a 15 MHz
linear transducer. The end-diastolic and end-systolic diameters
were determined, and stiffness was estimated as the fractional
change in diameter.
Serum Lipid and Glucose Content
Mice were fasted for 6 h prior to blood withdrawal. Total
chosterol, LDL-cholesterol, and triglycerides were measured with
kits from Wako Diagnostics, Inc. (Richmond, VA) in 96-well
micro-titration plates. For total and LDL cholesterol fractions,
serum samples were diluted 6-fold to allow values to fall within the
Figure 4. Oxidized LDL and Lipid peroxidation levels in ApoE
2/2 and ApoE
2/2 Nrf2
2/2mice. (A) oxLDL levels were quantified in the serum
of mice that were fed a high fat diet for 20 weeks by ELISA. (B) Lipid peroxidation was assessed by quantifying malondialdehyde (MDA) in the liver of
ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice after 20 weeks on a high fat diet. *p,0.05 by a two-tailed Student’s t-test. N=12 per group. Values represent
mean6SEM.
doi:10.1371/journal.pone.0003791.g004
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glucose reagent (Alfa Wassermann, West Caldwell, NJ) and
analyzed using the ACE chemistry analyzer.
Serum oxLDL and Lipid Peroxidation Measurements
MDA-modified oxLDL was measured using the oxidized LDL
ELISA kit (ALPCO Diagnostics, Salem, NH), as described by the
manufacturer. For lipid peroxidation measurements, liver tissues
were isolated and homogenized in 10 mL/mg ice-cold PBS
containing 5 mM butylated hydroxytoluene to inhibit ex vivo
oxidation. MDA was assessed by a thiobarbituric acid (TBARS)
assay kit (Zeptometrix, Buffalo, NY). Protein concentration was
determined by Bradford assay and the value of MDA was
normalized to mg protein used in the assay.
In vitro AcLDL Uptake Assay
Bone marrow-derived macrophages were isolated and cultured.
Macrophages were incubated with Alexa 488-conjugated AcLDL
(Invitrogen, Carlsbad, CA) in RPMI 1640 medium containing
10% FBS and Pen/Strep for 24 h at 37uCi n5 %C O 2. Cells were
Figure 5. Uptake of AcLDL by bone marrow-derived macrophages from ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice. Macrophages were
incubated with fluorescently-labeled AcLDL for 24 h at 37uC, and AcLDL uptake was assessed by flow cytometry. (A) Representative histograms of
fluorescence intensity. (B) Average relative fluorescence intensity of N=5 mice per group. *p,0.05 by a two-tailed Student’s t-test. Values represent
mean6SEM.
doi:10.1371/journal.pone.0003791.g005
Nrf2 Promotes Atherosclerosis
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and Nqo1 (D) in bone marrow-derived macrophages, was assessed by quantitative PCR. Macrophages from ApoE
2/2 and ApoE
2/2 Nrf2
2/2 mice were
incubated with 50 mg/ml oxLDL for 24 h at 37uC. (E) Representative images of CD36 immunohistochemistry of aorta cross-sections from ApoE
2/2 and
ApoE
2/2 Nrf2
2/2 mice that were fed a high fat diet for 20 weeks. (F) Quantification of CD36 staining intensity. *p,0.05 by a two-tailed Student’s t-
test. N$3 per group. Values represent mean6SEM.
doi:10.1371/journal.pone.0003791.g006
Nrf2 Promotes Atherosclerosis
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(BD Biosciences, San Jose, CA).
Gene Expression
Bone marrow-derived macrophages were incubated with
50 mg/ml oxLDL (Intracel, Frederick, MD) for 24 h at 37uC.
Total RNA was isolated, using the RNeasy mini kit (Qiagen,
Valencia, CA), and cDNA was generated using Multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA). Gene
expression was measured using assays on demand probe sets
(Applied Biosystems), and reactions were analyzed using the ABI
7000 Taqman system. b-actin was used for normalization.
Immunohistochemistry
Paraffin-embedded cross-sections of the aortic root were stained
with a phycoerythrin (PE)-conjugated mouse monoclonal CD36
(ME542) antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). Images were captured on an Olympus BX60 microscope,
equipped with a QImaging Retiga EXi camera, and staining
intensity was measured using Image-J software.
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